Vontobel Holding
SUPN icon

Vontobel Holding’s Supernus Pharmaceuticals SUPN Stock Holding History

Vontobel Holding’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,419
Closed -$228K – 1542
2026
Q1 		$228K Buy
4,419
+70
+2% +$3.56K ﹤0.01% 1076
2025
Q4 		$216K Buy
+4,349
New +$211K ﹤0.01% 1288

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Vontobel Holding's SUPN Position: Q2 2026 in Review

Vontobel Holding sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 4,419 shares — an estimated $228K sold.

Vontobel Holding first reported a position in SUPN in Q4 2025 and held it in 2 quarters. The position peaked at $228K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Vontobel Holding reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vontobel Holding sold 4,419 Supernus Pharmaceuticals shares in Q2 2026, an estimated $228K.
  • Vontobel Holding first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Vontobel Holding's Supernus Pharmaceuticals position peaked at $228K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.